FDA Approves New Radioligand Therapy and Diagnostic for mCRPC

FDA Approves New Radioligand Remedy and Diagnostic for mCRPC

The US Food and Drug Administration (FDA) has approved a new radioligand treatment for certain men with metastatic castration-resistant prostate cancer (mCRPC), as well as a new radioligand diagnostic agent for use in imaging to identify men who are suitable for this treatment. The new therapy is lutetium Lu 177 vipivotide tetraxetan (Pluvicto, from Advanced…